Betovate CL

Betovate CL0.1%+1%

Ointment

Betamethasone + Clotrimazole

GlaxoSmithKline

Product Code : 2179
MRP 29.31
10% Off
Best PriceTk
/
Out Of Stock
1
Section

Alternatives

See All
Product Image
10% Off

Bet-CL0.1%+1%

Betamethasone + Clotrimazole

ACME Laboratories Ltd.

54.00
60.00
Add to cart
Product Image
10% Off

Betson-CL0.1%+1%

Betamethasone + Clotrimazole

Opsonin Pharma Ltd.

26.46
29.40
Add to cart
Product Image
10% Off

Betavate-CL0.1%+1%

Betamethasone + Clotrimazole

Drug International Ltd.

26.18
29.09
Add to cart
Product Image
10% Off

Topibet CL0.1%+1%

Betamethasone + Clotrimazole

Eskayef Bangladesh Ltd.

31.50
35.00
Add to cart
Section

Medicine overview

Indications of Betovate CL 0.1%+1%

This topical preparation is indicated for the topical treatment of inflammatory dermal infections like- Tinea pedis Tinea cruris Tinea corporis etc.

Theropeutic Class

Betamethasone & Combined preparations

Pharmacology

Clotrimazole is a broad-spectrum antifungal agent used for the treatment of superficial infections caused by species of pathogenic dermatophytes, yeasts and Malassezia furfur. The mechanism of action involves inhibition of the synthesis of ergosterol, a major sterol in the fungal cell membrane. This leads to instability of the cell membrane and eventual death of the fungus.Betamethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. But the exact mechanism of action of corticosteroids is not clearly known.

Dosage & Administration of Betovate CL 0.1%+1%

Sufficient cream or ointment should be applied onto the affected and surrounding skin areas twice a day, in the morning and evening, for 2 weeks in tinea cruris and tinea corporis and for 4 weeks in tinea pedis. The use of cream for longer than four weeks is not recommended.

Dosage of Betovate CL 0.1%+1%

Sufficient topical preparation should be applied onto the affected and surrounding skin areas twice a day, in the morning and evening, for 2 weeks in tinea cruris and tinea corporis and for 4 weeks in tinea pedis. The use of this cream for longer than four weeks is not recommended.The safety and effectiveness of the preparation have not been established in children below the age of 12 years.

Interaction of Betovate CL 0.1%+1%

No information is available of drug interaction.

Contraindications

This topical preparation is contraindicated to those patients who are sensitive to any of its components or to other corticosteroids or to imidazoles. If irritation or sensitization develops with the use of the cream, treatment should be discontinued and appropriate therapy instituted. The cream is contraindicated in facial rosacea, acne vulgaris, perioral dermatits, perianal and genital pruritus, napkin eruptions and bacterial or viral infections. Systemic absorption of topical corticosteroides can produce reversible hypothalmic-pituitary-adrenal (HPA) axis suppression. If HPA axis suppression is noted, an attempt should be made to withdraw the drug or to reduce the frequency of application. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their large skin surface to body mass ratios.

Side Effects of Betovate CL 0.1%+1%

Adverse reactions reported for the preparation in clinical trials were paresthesia in 1.9% of patients, rash, edema and secondary infection, each in less than 1% of patients. Other adverse reactions reported with the preparation were burning and dry skin in 1.6% of patients and stinging in less than 1% of patients

Pregnancy & Lactation

Pregnancy: Catagory C. In the first trimester of pregnancy, clotrimazole should be used only when it is essential for the welfare of the patient. Administration of clotrimazole to a small number of women in the 2nd and 3rd trimesters of pregnancy has produced no obvious untoward effect on the course of the pregnancy or on the fetus. Lactation: Although systemic absorption following topical or vaginal administration is low, caution should be exercised when clotrimazole is administered to nursing mothers as there is no information on whether or not clotrimazole is excreted in breast milk.

Precautions & Warnings

Not recommended for use in diaper dermatitis and under occlusion. Pregnancy and lactation. If irritation or sensitization develops with the use of the cream, treatment should be discontinued and appropriate therapy instituted.

Overdose Effects of Betovate CL 0.1%+1%

Acute overdose with the cream is unlikely and would not be expected to lead to a life-threatening situation. The cream should not be used for longer than the prescribed time period.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Use In Special Populations

The safety and effectiveness of the preparation has not been established in children below the age of 12 years.

Drug Classes

Betamethasone & Combined preparations

Mode Of Action

Clotrimazole is a broad-spectrum antifungal agent used for the treatment of superficial infections caused by species of pathogenic dermatophytes, yeasts and Malassezia furfur. The mechanism of action involves inhibition of the synthesis of ergosterol, a major sterol in the fungal cell membrane. This leads to instability of the cell membrane and eventual death of the fungus. Betamethasone dipropionate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. But the exact mechanism of action of corticosteroids is not clearly known.

Pregnancy

There is inadequate evidence of safety in pregnancy. Clotrimazole has no teratogenic effect in animals but is foetotoxic at high oral doses. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development. Hence the cream should only be used in pregnancy if the benefit justifies the potential risk to the fetus and such use should not be extensive,i.e. in large amounts or for long periods. It is not known whether the components of the preparation are excreted in human milk and therefore caution should be exercised when treating nursing mothers.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.